Medipure Announces Formation of Scientific Advisory Board

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 10, 2015) -

THIS PRESS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES, AND SHOULD NOT BE DISSEMINATED WITHIN THE U.S.

Medipure Holdings Inc. (CSE:MDH) is pleased to announce that its subsidiary, Medipure Pharmaceuticals Inc. ("Medipure," or the "Company"), has completed the formation of its Scientific Advisory Board (the "SAB"). The members of the SAB will utilize their scientific expertise to advise Medipure regarding the development of the Company's products, most notably proprietary cannabinoid formulations usable within prescription therapeutics for the treatment of anxiety and related mental illnesses.

Initially, Medipure's SAB will be composed of three members: Dr. Alasdair Barr, PhD; Dr. William Paneka, MD, MSc; and Dr. Xia Zhang, MSc, PhD, and MD. The Company also has a Memorandum of Understanding in place with both Dr. Barr and Dr. Paneka regarding their pre-clinical and clinical research, as described in a press release entitled "Medipure Announces MOU with Renowned Clinical Scientists to Develop Prescription Therapeutics," dated May 21, 2015. Biographies of Dr. Barr and Dr. Paneka are available within that release.

Dr. Xia Zhang is a Professor within the University of Ottawa's Departments of Psychiatry and Cellular and Molecular Medicine. He is also Director of the Translational Neuroscience Laboratory at the University's Institute of Mental Health Research. Dr. Zhang is considered to be a global leader in the field of cannabinoid research and associated brain mechanisms related to mental illness, specifically memory malfunction, anxiety and mood disorders. He has received the 'New Investigator' award from the Canadian Institute of Health Research (the "CIHR"), the 'Innovations' award from the Canadian College of Neuropsychopharmacology, the 'Independent Investigator' award from the National Alliance for Research on Schizophrenia and Depression in the United States, and the 'Chang-Jiang Lecture Professor' award from the Chinese Education Ministry. He is also the Principal Investigator on 15 peer reviewed grants from the CIHR, the National Sciences and Engineering Research Council of Canada, the Canadian Foundation for Innovation, and the Heart and Stroke Foundation of Canada. Dr. Zhang's research ultimately seeks to discover how to harness the power of cannabinoids for the treatment of memory malfunction, anxiety, mood disorders, and other ailments.

About Medipure Holdings Inc.

Medipure Holdings Inc. is a biopharmaceutical company focused on developing and marketing novel cannabinoid-based prescription medicines through its subsidiary, Medipure Pharmaceuticals Inc. Medipure is creating a network of strategic partnerships with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based bioactive molecules into prescription pharmaceutical products. Medipure will bring novel prescription medicines to market, providing patients with serious conditions valuable solutions that make a real difference to quality of life. Medipure will also seek to maximize the value of developed products through rapid, cost-effective product development, addressing market needs, and establishing further strategic partnerships as the company matures. Although Medipure has applied to Health Canada for a license to produce and distribute medical marihuana under the Marihuana for Medical Purposes Regulations, it has not yet received such a license and there is no guarantee that such a license will be granted to Medipure by Health Canada.

Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of securities laws. This information is based on certain assumptions regarding expected growth, results of operations, performance, and business prospects and opportunities. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the companies cannot provide any assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release and the companies disclaim any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.